Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07668336 · ClinicalTrials.gov registry record · Phase 3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Not yet
- Registry status
- Phase 3
- Development phase
- 170
- Enrollment target
NCT07668336 is a Phase 3 study that has not yet begun recruiting, run by Eli Lilly and Company. The registered enrollment target is 170 participants.
The verdict
NCT07668336, a Phase 3 study, has not yet begun recruiting, sponsored by Eli Lilly and Company.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 170 participants
- Enrollment target
Study Summary
This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.
Interventions
- DRUG Orforglipron
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2026-09 |
| Est. Completion | 2030-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07668336
The ClinicalTrials.gov registry entry for NCT07668336 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Orforglipron is the first listed.
NCT07668336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07668336 about?
NCT07668336 is a clinical study titled "A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes". This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in th...
What is the current status of trial NCT07668336?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 170 participants. The study started on 2026-09. Estimated completion is 2030-03.
What interventions are being tested in trial NCT07668336?
The interventions under investigation include: Orforglipron (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07668336?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.